

---

**P-30; ACTIVITY AND DISTRIBUTION OF CELLS INFILTRATING TC-1 TUMOURS AFTER CHEMOTHERAPY AND SUBSEQUENT IL-12 IMMUNOTHERAPY**

Marie Indrová<sup>1</sup>, Elzbieta Pajtasz-Piasecka<sup>2</sup>, Joanna Rossowska<sup>2</sup>, Jana Bieblova<sup>1</sup>, Milan Reiniš<sup>1</sup>

<sup>1</sup>*Institute of Molecular Genetics AS CR, v.v.i., Prague 4, Czech Republic*

<sup>2</sup>*Institute of Immunology and Experimental Therapy, Polish Acad. Sci., Wroclaw, Poland*

**Methods:** Moderately immunogenic HPV-16-associated TC-1 tumour mimicking human HPV-16-associated neoplasms was used to examine the effect of local interleukin-12 gene therapy with a genetically modified tumour cell vaccine for the treatment of minimal residual tumour disease, obtained after cytoreductive chemotherapy (CMRTD) with ifosfamide derivative CBM-4A, on the distribution and activity of tumour-infiltrating cells.

**Results:** After chemotherapy, histological and immunohistological examinations showed a decrease or disappearance of CD4<sup>+</sup> and CD8<sup>+</sup> T cells as well as macrophages. The administration of the vaccine led to the abundance of macrophages and renewal of CD8<sup>+</sup> and CD4<sup>+</sup> cells in the tumour nodules. The FACS analysis of tumour-infiltrating cells showed a significant increase in CD11c<sup>+</sup> cells after chemotherapy and

---

subsequent immunotherapy. Moreover, CD45<sup>+</sup> tumour-infiltrating cells isolated from the treated animals exhibited, after short-term *in vitro* precultivation, renewed cytotoxic and proliferation potential.

**Conclusion:** These findings contribute to the relevance of the treatment of CMRTD with genetically modified cellular vaccines.

**Acknowledgement:** This work was supported by grants: 301/06/0774 (GA CR), Joint project PAN and AS CR (2006-8).